Physician profile
Mohammad Vakassi
NPI 1184602096
$3,021.51
in general payments reported to CMS, 2019-2025
27 companies · $83.76 in 2025
The $83.76 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $208 · 2021: $302 · 2022: $930 · 2023: $620 · 2024: $17.71 · 2025: $83.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $680.38 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $387.49 | 2019-2023 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $304.07 | 2022-2025 | |
| Pfizer INC. | $275.02 | 2019-2023 | |
| Amgen INC. | $261.47 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $122.75 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $118.24 | 2021-2023 | Verquvo |
| Abbott Laboratories | $103.56 | 2022-2024 | Jot Dx |
| Boston Scientific Corporation | $90.99 | 2022-2023 | Watchman Access System, Watchman |
| Gilead Sciences, INC. | $85.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $58.47 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $51.10 | 2019 | |
| Covidien Lp | $44.53 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $42.11 | 2023 | Opsumit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $40.92 | 2021-2023 | Linq II |
| Edwards Lifesciences Corporation | $37.98 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kestra Medical Technology Services, INC. | $29.78 | 2022-2023 | Assure Wcd |
| Otsuka America Pharmaceutical, INC. | $28.64 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $21.90 | 2022 | |
| Daiichi Sankyo INC. | $20.31 | 2023 | Injectafer |
| Cvrx, INC. | $18.26 | 2022 | |
| Esperion Therapeutics, INC. | $17.42 | 2025 | Nexletol |
| Csl Behring | $16.53 | 2021 | |
| Amarin Pharma, INC. | $16.42 | 2021 | |
| Novo Nordisk INC | $13.04 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Vakassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.